Marinus Pharmaceuticals Inc (MRNS) Company Profile & Statistics

Marinus Pharmaceuticals Inc
MRNS
(Nasdaq - US)
Closed
0.32
+0.00 (+0.37%)
in:usd•As of: Nov 22, 2024 15:57 UTC -5
Open
0.33
High
0.33
Low
0.32

About Marinus Pharmaceuticals Inc

CEO

Scott Braunstein

Headquarters

5 radnor corporate center, suite 500

radnor, pa 19087, united states

Auditor

Ernst & Young LLP

Employees

166

Share Holders

Website

www.marinuspharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.

Marinus Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	17.85M
Enterprise Value	70.06M
Enterprise Value/EBITDA (ttm)	-0.57
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	0.57
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	90.08%
Operating Margin (ttm)	-440.29%
Profit Margin (ttm)	-453.22%
Return on Equity (ttm)	-7831.35%
Return on Invested Capital (ttm)	-416.03%
Return on Assets (ttm)	-120.74%

Income Statement

Revenue (ttm)	31.47M
Revenue Per Share (ttm)	0.57
Gross Profit (ttm)	28.37M
EBITDA (ttm)³	-122.68M
Net Income Avi to Common (ttm)	-140.49M
Diluted EPS (ttm)	-2.47

Share Statistics

Beta (5Y Monthly)	1.26
52-Week Change	-94.72%
S&P500 52-Week Change	30.93%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	55.19M
Dividend Yield	0.00%
Float ⁴	52.17M
% Held by Insiders	5.46%
% Held by Institutions	98.80%

Balance Sheet

Total Cash (mrq)	42.18M
Total Cash Per Share (mrq)	0.76
Total Debt (mrq)	94.39M
Total Debt/Equity (mrq)	-141.43%
Current Ratio (mrq)	1.66%
Quick Ratio (mrq)	1.47%
Book Value Per Share (mrq)	-1.21

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.53
Free Cash Flow (ytd)	-88.91M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Marinus Pharmaceuticals Inc

Trade With A Regulated Broker